This comorbid model produces marked metabolic dysfunction, including hyperglycemia, hyperinsulinemia, increased insulin resistance, and dyslipidemia, with decreased HDL-CH and elevated TGs and VLDL-CH, accompanied by impaired redox balance. This evidence concerns the gene C4B and hyperinsulinism.